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Summary Intravenous injection of Corynebacterium parvum (C. parvum) 4 days after s.c. inoculation of
5 x 105 cells derived from the immunogenic fibrosarcoma FSA/R induced tumour growth inhibition over a
period of 21 days in syngeneic C3H/Buf mice. This was not accompanied by a change in the proportions of
host cells within the tumour, but the activation state of tumour-infiltrating macrophages was increased
followizig C. parvum therapy. Two macrophage subpopulations were identified in FSA/R tumours after
fractionation by unit gravity velocity sedimentation. After i.v. C. parvum therapy the tumour-infiltrating
macrophage subpopulation which sedimented between 1 and 6 mmh-1 was consistently activated as
determined by measurement of Fc receptor avidity. Other intra-tumour macrophages were generally
unaffected by C. parvum treatment. We have previously shown that the host cell fraction sedimenting between
1 and 6 mmh-I is enriched with monocytes and the data presented in this paper suggest that these cells may
enter the tumour in a pre-activated state following intravenous C. parvum therapy.
Many experimental (Kerbel & Pross, 1976; Moore
& Moore, 1977) and human (Wood & Gollahon,
1977; Wood et al., 1978) tumours exhibit a
significant level of macrophage (mp) infiltration
and this is believed to be a manifestation of the
host response (Alexander, 1976) involved in the
restraint of primary tumour growth and metastatic
dissemination.
Although the spontaneous regression of
experimental virus-induced murine tumours has
been demonstrated to be associated with alterations
in the activation status of tumour-infiltrating mg
(Russell & McIntosh, 1977) no such correlation has
before been demonstrated in either chemically-
induced tumours or those of spontaneous origin.
However, mg isolated from non-immunogenic
tumours have been demonstrated to stimulate
tumour cell growth rate in vitro whilst those
isolated from immunogenic tumours were cytostatic
(Mantovani, 1978). In human cancer patients a
correlation has been found between the number of
mp present within primary breast tumours and
melanomas and extent of subsequent tumour
dissemination (Gauci & Alexander, 1975).
These data indicate that mg associated with
tumours may exert anti-tumour functions under the
appropriate circumstances, but generally even those
tumours which contain very high levels of
Macrophages, isolated from such progressively
growing chemically-induced rat (Moore & Moore,
1980) and mouse tumours (Moore & McBride,
1980), exhibit functions which suggest that these
cells are at an arrested state of differentiation such
that they are not fully activated. These tumours do
not generally regress spontaneously and in the
present study we have used immunotherapy-induced
inhibition of tumour growth as a model to
investigate the role that m? may play in this
process.
It has been shown previously that inhibition of
tumour growth following systemic administration of
Cornyebacterium parvum (C. parvum) is not
associated with an increase in the numbers of
tumour-infiltrating mp (Thomson et al., 1979). We
confirm this but also demonstrate that C. parvum
induced-tumour growth inhibition is associated with
an enhancement of tumour mp activation state.
The particular subset of mp that is activated
maximally with regard to Fc receptor function is
that with sedimentation characteristics of the
recently-emigrated monocyte and this suggests that
C. parvum therapy causes peripheral pre-activation
of monocytes before they enter the tumour.
Materials and methods
Mice
Inbred C3H/Buf/Kam strain mice aged between 6-
10 weeks were used in all experiments. These mice
were taken from a colony established from breeding
pairs obtained from the laboratory where the
FSA/R tumour was induced.
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Tumour
The tumour used (FSA/R) was a highly
immunogenic fibrosarcoma originally induced in
C3H/Buf/Kam mice by methylcholanthrene (Suit &
Kastelan, 1970). It was maintained by serial
passage in syngeneic mice and the tumour was used
between passage 13 and 19.
C. parvum treatment
Tumours were induced in groups of 10 mice by s.c.
inoculation of 5 x 105 in vivo derived tumour cells.
Four days later 0.25 mg of Corynebacterium
parvum (C. parvum, Burroughs Wellcome Ltd.,
Beckenham, Kent, England), suspended in 0.25 ml
PBS was injected in the tail veins of the test group.
Control mice received no treatment.
Tumour growth was monitored by taking the
average of opposing diameters of tumours
measured with skin calipers. Both groups of mice
were monitored for up to 22 days of tumour
growth and groups were killed by cervical
dislocation at various intervals for tumour excision
and analysis of intra-tumour host cells.
Cellfractionation
Following excision non-necrotic tumour tissue was
pooled within groups and single cell suspensions
prepared by enzymatic disaggregation with a
mixture of Dispase/DNase as previously described
(Moore & McBride, 1980) for 30min at room
temperature. After washing and resuspension 108
cells were subjected to unit gravity velocity
sedimentation (Miller & Phillips, 1969) for 3 h and
fractions were collected which contained cells
sedimenting over the range of 1 to 14mmh-'.
The composition of cell suspensions before and
after fractionation was determined by differential
counting of Jenner-Giemsa stained cytospin films
prepared from cells incubated for 1 h at 37 'C with
1.1 um diam. polystyrene latex in medium
containing 20% foetal calf serum (FCS).
Preparation ofMacrophage monolayers
1) From non-fractionated tumour cell suspensions:
Cells were suspended at 2 x 106 ml-' in MEM
containing 20% FCS and 0.05% Dispase to prevent
adherence of tumour cells and the suspension pre-
warmed at 37°C. One-half millilitre of the cell
suspension was then dispensed in pre-warmed
Costor tissue culture plates (Arnold R. Horwell Ltd.,
London, England) and the plates incubated for
10min before washing off the non-adherent cells
x 3 with Hanks solution and finally adding 1 ml of
Hanks solution before EA rosetting. These mp were
denoted as rapidly adherent.
2) Fromfractionated tumour cell suspensions:
Cells isolated after velocity sedimentation were
suspended at 5 x 105 ml-' in MEM containing 20%
FCS and 0.05% Dispase. This cell suspension was
treated as above but the m(p were allowed to
adhere for 30min at 37°C to allow relatively less
adherent mg and monocytes to attach. Both
procedures gave monolayers made up of more than
85% of phagocytic mononuclear cells as determined
by 1.1,um diam. polystyrene latex uptake (Moore &
McBride, 1980).
Measurement ofFc receptor avidity
Fc receptor (FcR) avidity was measured as
previously described (Moore & McBride, 1980).
Briefly, aliquots of bovine erythrocytes were
sensitized with doubling dilutions of hyperimmune
rabbit IgG. These EA suspensions were then
sedimented by centrifugation onto mg monolayers
and after an incubation for 30min at room
temperature excess EA were washed off and the
number of cells forming rosettes (EA RFC) was
enumerated microscopically.
For each mg population the EA50 value, as a
measure of FcR avidity, was calculated as follows:
EA50=1000 Concentration of sensitising
antibody, in jig ml- required
to induce 50% of total EA RFC
to form rosettes.
In addition to the standard technique where 8
batches of EA sensitised with antibody diluted over
the range of 1/8 to 1/1024 a modified technique was
used to measure FcR avidity of monolayers
prepared from fractions isolated after velocity
sedimentation. This was performed by preparing
two mg monolayers and measuring the number of
cells forming rosettes with EA sensitised with
antibody diluted at 1/16 (EA16) or 1/256 (EA256).
The results were expressed for each cell monolayer
by use of the following formula:
% of cells forming rosettes with EA256 x 100
% of cells forming rosettes with EA16
Results
I.v. inoculation of 0.25 mg of C. parvum 4 days after
a s.c. inoculation of 5 x 105 FSA cells caused
inhibition of tumour growth (Figure 1). Typically C.
parvum treatment had little influence on the earlyFcR EXPRESSION ON MURINE INTRA-TUMOUR MACROPHAGES 799
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Figure 1 Effect of i.v. C. parvum treatment on growth
rate of FSA/R tumours. 5 x 10' tumour cells were
injected s.c. to groups of 8 mice at Day 0 and 0.25 mg
of C. parvum was injected at Day 4 to the test group.
Tumour size expressed as the mean of opposing
diameters. Error bars+s.e. of the mean of 8 tumours
in each group.
stages of tumour growth with its effects becoming
obvious 10 days after C. parvum was given.
After enzymatic disaggregation of tumour tissue
the host cell content of the resultant cell suspension
was determined by differential counting (Table I). It
was not possible to detect a difference in cellular
composition between tumour cell preparations
derived from control and C. parvum-treated animals
during the period of tumour growth inhibition
following Day 14 after tumour inoculation.
Fc receptor avidity ofunfractionated tumour m(p
The activation state of rapidly adherent non-
fractionated mp within individual tumours was
Table I Differential count of cell
measured between 13 and 22 days after tumour
inoculation. A consistent increase in EA50 values
was detected for those mp isolated from tumours
which were undergoing C. parvum induced growth
inhibition (Table II). The mean increase in EA50
was 67% (range 25%-144%) and was highly
significant (P<0.001) by Student's t-test.
Velocity sedimentationfractionation of tumour mg
When cell suspensions from either C. parvum
treated or control tumours were subjected to
velocity sedimentation for 3h, no difference could
be detected between them with respect to the
elution profiles of total cells or EA rosette forming
cells. In both situations 2 major cell peaks were
consistently found (Figure 2b). The smaller peak
sedimenting at 1 to 5 mm h- 1 contained mainly
host cells, whilst a larger more rapidly sedimenting
peak (>6 mmh'- ) contained tumour cells and large
mp. Although this second peak contained only 20%
mnp, in absolute numbers 50% of the total mp in
the tumours sedimented in excess of 6mmh- .
Rapidly sedimenting large, vacuolated mp were
found distributed throughout the lower regions of
the gradient with sedimentation velocities of up to
14 mm h'- (Table III).
After isolation of mp from each fraction of the
gradient, their FcR activation level was determined
by evaluating the ratio of the number of cells
forming EA rosettes with ORBC sensitized by IgG
diluted 1/16 to the number of cells forming rosettes
with ORBC sensitized by a 1/256 dilution of IgG.
This method was used because it could be carried
out on a limited number of mg, and therefore was
ideal for assaying small fractions isolated from the
sedimentation procedure. Fractionation of control
tumour suspensions from untreated animals
demonstrated that the more highly activated mp
sedimented at 6 to 10mmh- . Within the tumour
cell suspension prepared from C. parvum treated
animals a shift in the sedimentation profile of the
activated mg population was observed when
suspensions prepared from tumours
excised from control or C. parvum treated mice
Polymorpho-
Macrophages/ nuclear
7Thmour cells monocytes Lymphocytes neutrophils
Control 80+4.4a 12.5+2.8 5.0+3.4 1.0+1.1
C. parvum treated 83+3.7 10.5+2.7 4.5+2.0 2.0+ 1.5
Each group is the mean of differential counts on 10 different tumour cell
preparations.
a+s.d.
Differences between each group were not significant in a Student's t-test.
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Table II EA50 of unfractionated tumour-infiltrating macrophages
Days after EA50
tumour transplant* EA50 control C. parvum treated** % Increase
13 305 380 25
14 322 448 39
16 241 588 144
17 333 650 95
17 292 500 71
17 294 500 70
17 277 385 39
17 185 286 55
21 223 428 92
21 294 422 44
22 339 550 62
Mean (±s.e.) 282 (± 15) 467 67
(i±31)*** (±10)
*5 x 10' in vivo derived tumour cells inoculated s.c. on Day 0.
**0.25 mg C. parvum injected i.v. on Day 4.
***P<0.001 when the means of the EA50 values are compared by
Student's t-test.
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Figure 2 Velocity sedimentation fractionation of
tumour infiltrating macrophages. a. Fc receptor
avidity: ( ) C. parvum; (-----) Control. b. (U-----U)
% ofEA rosette forming cells per fraction; (M U)
total cells per fraction x 10-; (El El) total
EA rosette forming cells per fraction.
tumours were tested during the period of growth
inhibition. This was largely restricted to those mp
present within the major host cell fraction
containing cells sedimenting at 1 to 5.5 mm h-'. In
the experiment shown in Figure 2a, a less marked
enhancement of FcR avidity was also found in the
mp sedimenting between 6 and 10mmh-' but this
increase was not a consistent finding in all C.
parvum-treated tumours. Macrophages sedimenting
in excess of 11 mmh-' were unaffected by C.
parvum therapy.
Discussion
The host cell content of immunogenic tumours
undergoing C. parvum-induced growth inhibition
does not differ significantly from progressor
tumours growing in untreated syngeneic mice. C.
parvum-induced tumour growth inhibition in this
syngeneic system is however, T-cell dependent
(McBride et al., 1980) and thus one might expect
some qualitative, if not a quantitative change, in
those intra-tumour host cells representative of the
cellular immune system. Changes in the activation
state of tumour infiltrating mp have been shown to
be intimately associated with regression or
progression of MSV tumours (Russell et al., 1977)
and in the present study we have demonstrated
changes in this cell population to be associated with
inhibition of growth of a chemically induced
tumour following i.v. immunotherapy with C.
parvum. Measurement of the activation state of
unfractionated mp isolated from regressor or
progressor tumours indicated that when means of
the two groups were compared a 67% increase in
FcR avidity was found.
We have previously demonstrated that tumour
infiltrating mononuclear phagocytes are
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Table III Differential count on Day 14 fractionated control and C. parvum treated tumours
Polymorphonuclear
Tumour cells Macrophages Lymphocytes neutrophils
% (cells x 104) % (cells x 104) % (cellsx 104) % (cellsx 104)
CONTROL
Unfractionated 82 14 3 1
I 1-5.5 mmh1 23 (131) 48 (274) 23 (131) 6 (34)
II 5.5-8.5 mmh1 78 (640) 21 (172) 1 (8.2) 0 (0)
III 8.5-11.5 mmh 95 (979) 5 (56)
IV 11.5-14 mmh-1 97 (412) 3 (22)
C. parvum
TREATED
I 1-5.5 mm h 33 (249) 40 (302) 26 (196) 1 (8)
II 5.5-8.5 mmh 82 (1013) 17 (209) 1 (12) 1.5 (6)
III 8.5-11.5 mm h 95 (1064) 5 (51)
IV 11.5-14 mmh-1 97 (425) 3 (24)
Unfractionated 82 13 4 1
heterogeneous with respect to FcR avidity (Moore
& McBride, 1980). In that study we demonstrated
the presence of two populations of mq exhibiting
different activation levels of FcR and in the present
study we determined which mp subpopulation was
the target for C. parvum induced activation to gain
some insight into how C. parvum was influencing
mq differentiation within the tumour micro-
environment.
When tumours from C. parvum-treated animals
were subjected to fractionation by unit gravity
velocity sedimentation no difference could be
detected in the distribution of EA rosette forming
cells when rosettes were formed using ORBC
sensitised with high concentrations of antibody.
However, when the mq were rosetted with ORBC
sensitised with low levels of antibody, only the
activated mp formed rosettes. This technique
demonstrated that the smaller sized population of
phagocytic cells within the tumour which
sedimented at 1 to 5 mm h- exhibited the greatest
increase in activation state in response to C. parvum
treatment. An eight-fold increase in FcR avidity
was detected within this population in contrast to a
mean 67% increase in the rapidly adherent non-
fractionated mp preparations. This was caused by
the presence within monolayers derived from non-
fractionated cells of large, rapidly sedimenting mgp
which comprise 50% of the total within the
tumour. These mp are unaffected by C. parvum
therapy and consequently their presence results in
an apparent lowering of FcR avidity when
heterogeneous monolayers are examined. Although
cell monolayers analysed in these experiments were
routinely >85% phagocytic it has to be considered
that a minor non-phagocytic cell population
expressing FcR that increase in avidity after C.
parvum treatment may be responsible for the
observed changes. Response to C. parvum treatment
in this model is T-lymphocyte dependent (McBride
et al., 1980) and tumour infiltrating T-lymphocytes
may be activated simultaneously with cells of the
mononuclear phagocyte series. Activated T-
lymphocytes (Yoshida & Anderson, 1972) and B-
lymphocytes (Basten et al., 1972) express FcR
which would form rosettes under the conditions
used, i.e. with ORBC sensitised with high
concentrations of antibody if they did contaminate
the mg monolayers. It is unlikely however, that the
presence of these cdontaminating lymphocytes would
contribute to the FcR avidity changes observed in
the monolayers isolated from the slower
sedimenting lymphocyte enriched fractions.
Although activation of T-lymphocytes does increase
FcR expression, this level is still 10 times less than
that of proteose peptone-elicited peritoneal mg
(Anderson & Grey, 1974). Earlier studies with the
FSA/R tumour (Moore & McBride, 1980) indicated
that the FcR avidity of the slower sedimenting
tumour infiltrating mg in control animals was at
least equal to that of proteose peptone-elicited mp.
In the present study we are measuring increases in
excess of this revel of FcR expression which
eliminates the possibility of activated T-lymphocyte
interference in the assay.
Results of our earlier study indicated that the
intra-tumour phagocytic mononuclear cells
sedimenting at the same velocity as those activated
by C. parvum therapy, contain mqp which are less
differentiated than the larger more rapidly
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sedimenting cells and probably represents cells
which have recently entered the tumour from the
circulating monocyte pool. Systemic administration
of C. parvum induces a generalised stimulation of
the reticuloendothelial system (Baum & Breese,
1976) and monocytes may therefore be activated
before extravasation to the solid tumour. We have
previously demonstrated that full activation of m?
is not achieved within the microenvironment of
FSA/R tumours when growing progressively
(Moore & McBride, 1980). The activation pathway
of the intra-tumour msp in C. parvum treated mice
may circumvent this problem by activating the m?
at a site distant to the tumour. If intra-tumour m?
differentiation is normally inhibited by the high
concentration of suppressor factors at the tumour
site (Spitalny & North, 1977) then C. parvum
induced mg activation may be occurring where
these factors are at an ineffective concentration.
Thus activated monocytes/macrophages may enter
the tumour where they are able to exert anti-
tumour mechanisms before being inactivated.
This work was supported by a grant from the Cancer
Research Campaign of Great Britain.
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